Research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
== Diagnosis == Doctors formerly diagnosed cachexia mainly by looking at changes in body weight. A person was considered to have cachexia if they had a low BMI or unwanted weight loss of more than 10%. However, weight alone is not always a reliable method. Factors like fluid buildup (edema), tumor size, and obesity can make it difficult to diagnose cachexia. These weight-based criteria do not account for muscle loss, which is a key part in cachexia. . To improve diagnosis of cachexia, experts proposed adding lab tests and symptom evaluations. With that, a person might have cachexia if they lost at least 5% of their total body weight in 12 months or had a BMI under less 22 kg/m2 with at least three of the following: weak muscles, fatigue, loss of appetite, low muscle mass, or abnormal labs. There have been attempts to define specific types of cachexia, such as cardiac cachexia, which can occur in people with congestive heart failure. However, it has no widely accepted definition.
For occupational exposures to strychnine, the Occupational Safety and Health Administration and the National Institute for Occupational Safety and Health have set exposure limits at 0.15 mg/m3 over an 8-hour work day. Because strychnine produces some of the most dramatic and painful symptoms of any known toxic reaction, strychnine poisoning is often portrayed in literature and film including authors Agatha Christie and Arthur Conan Doyle.
== Habitat and distribution == Xanthoria parietina is a cosmopolitan species reported from Australia, Africa, Asia, North America, and throughout much of Europe. In eastern North America and Europe, it is more frequently encountered near coastal locations, and in Southern Ontario, Canada, its reappearance has been attributed to increased nitrate deposition associated with industrial and agricultural developments. The species shows a strong preference for coastal habitats, where it benefits from marine aerosol deposition. In Maine, USA, X. parietina is abundant on gravestones near the ocean but declines sharply further inland. It becomes rare beyond 40 km (25 mi) from the coast in southwestern Maine and 130 km (81 mi) inland in eastern Maine. This inland distribution pattern is largely influenced by the deposition of marine-derived nutrients, particularly chloride and sodium, which are transported inland by wind and precipitation. In North America, the species was historically limited primarily to coastal regions—along the Atlantic coast from Newfoundland to Pennsylvania, along the Pacific coast from California to the Pacific Northwest, and in a small part of the Gulf coast in Texas. Within the Pacific Northwest, its traditional range was described as west of the Cascades, from the Willamette Valley to the Puget Sound region. Since the early 2000s, however, the species has been documented in several inland cities in Idaho, Washington, and parts of western Montana.
The Boston keratoprosthesis is the most widely used synthetic cornea to date with over 900 procedures performed worldwide in 2008. The Boston KPro was developed at the Massachusetts Eye and Ear Infirmary under the leadership of Claes Dohlman.
Sources: en.wikipedia.org
The move resulted in a backlash from the gaming community, and Firewatch was "review-bombed" on Steam. Ars Technica noted that the company previously stated on their website that they gave open permission to stream and monetize videos made while playing the game. On April 21, 2018, Campo Santo announced that they had been acquired by Valve and would subsequently move to Valve's Bellevue, Washington headquarters and continuing In the Valley of Gods as a Valve game. According to Vanaman and Rodkin, after the success of Firewatch, they started internal discussions of where they wanted to take their company. These discussions continued informally with third parties, including Valve's Robin Walker, Erik Johnson and Scott Lynch. These Valve employees suggested that Campo Santo could retain its own direction while being wholly within Valve, yet still draw from Valve's knowledge and expertise. Vanaman and Rodkin discussed this more formally with Valve, ultimately leading to the acquisition. Development on In The Valley of Gods was put on hold in July 2019, partially due to head writer Sean Vanaman moving to the writing team for Half-Life: Alyx, which had not been announced to the public at the time. In November 2019, it was noted by journalists that Claire Hummel, Jane Ng, and Rodkin had removed In the Valley of Gods from their Twitter profile descriptions. The game also disappeared from Campo Santo's website and the original announcement trailer was made private on YouTube, though the website and its Steam profile page were still available.
=== Other illnesses === According to a 2020 meta-analysis of 48 clinical trials, Pioglitazone and Roux-en-Y gastric bypass surgery were the two most effective treatments for non-alcoholic steatohepatitis; the analysis' authors based this conclusion on improvements to the non-alcoholic fatty liver disease scores of trial participants. A 2021 meta-analysis of three clinical trials found that Pioglitazone had not been proven effective to treat Alzheimer's disease.
== Bilateral and legislative anti-narcotics measures == In February 1987, Bolivia and the United States signed a broad outline of an agreement on a three-year, US$300 million joint plan aimed at eradicating 70 percent of Bolivia's known coca fields. The new program included a one-year voluntary eradication phase and a program in which coca growers would be paid US$350 in labor costs and US$1,650 in longer-term development assistance for each hectare of coca destroyed. According to the Department of State's Bureau of International Narcotics Matters, Bolivia exceeded the voluntary coca reduction target for the September 1987 to August 1988 period, destroying 2,000 hectares, or 200 more than required. To implement the 1987 agreement, the Paz Estenssoro government revamped the antidrug bureaucracy that had been established, incongruously, in 1981 during the García Meza regime. The National Council Against the Unlawful Use and Illicit Trafficking of Drugs (Consejo Nacional Contra el Uso Indebido y Tráfico Ilícito de Drogas—Conalid), presided over by the foreign minister, was charged with drawing up rules and regulations and creating new antidrug-trafficking measures. Two new secretariats were formed under Conalid. The Social Defense Subsecretariat (Subsecretaría de Defensa Social) was made subordinate to the Ministry of Interior, Migration, and Justice and charged with interdiction. It also centralized all the activities of the National Directorate for the Control of Dangerous Substances (Dirección Nacional para el Control de Substancias Peligrosas—DNCSP) and of the Umopar.
==== Majors and programs ==== Doctoral Communication Sciences and Disorders Audiology Physical Therapy Master's Communication Sciences and Disorders Speech-language Pathology Genetic Counseling Health Administration (in conjunction with the College of Medicine and the Lindner College of Business) Nutrition Sciences Transfusion and Transplantation Services Bachelor's Advanced Medical Imaging Technology Clinical Laboratory Science Clinical Laboratory Science – Distance Learning Communication Sciences and Disorders Dietetics Food and Nutrition Concentration in Exercise Science Concentration in Pre-Medicine Health Information Management – Distance Learning Health Sciences Sports and Biomechanics Concentration Exercise Science Concentration Certificate Clinical Laboratory Science Dietetics School of Social Work
Glucose is mainly metabolized by a very important ten-step pathway called glycolysis, the net result of which is to break down one molecule of glucose into two molecules of pyruvate. This also produces a net two molecules of ATP, the energy currency of cells, along with two reducing equivalents of converting NAD+ (nicotinamide adenine dinucleotide: oxidized form) to NADH (nicotinamide adenine dinucleotide: reduced form). This does not require oxygen; if no oxygen is available (or the cell cannot use oxygen), the NAD is restored by converting the pyruvate to lactate (lactic acid) (e.g. in humans) or to ethanol plus carbon dioxide (e.g. in yeast). Other monosaccharides like galactose and fructose can be converted into intermediates of the glycolytic pathway.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.